Role of polymorphisms of the IGF2 and IGFBP3 genes and risk of gastric carcinoma in China

Chinese Medical Journal

Volumn 127, Issue 3, 2014, Pages 412-416

  Gu, Jun ^a   Li, Mao Lan ^b   Dong, Ping ^a,b   Lu, Jian Hua ^a,b   Tan, Zhu Jun ^a,b   Wu, Xiang Song ^a,b   Mu, Jia Sheng ^a,b   Zhang, Lin ^a,b   Wu, Wen Guang ^a,b   Ding, Qi Chen ^a,b   Yang, Jia Hua ^a,b   Cao, Yang ^a,b   Ding, Qian ^a,b   Weng, Hao ^a,b   Liu, Ying Bin ^a,b  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gastric carcinoma; IGFBP3; Insulin like growth factor 2; Logistic regression; Polymorphisms

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CELL GROWTH; CELL PROLIFERATION; CHINA; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IGF2 GENE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOMA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; STATISTICAL MODEL; STOMACH TUMOR;

ADULT; AGED; CASE-CONTROL STUDIES; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR II; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS;

EID: 84893031006     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122955     Document Type: Article

References (29)

1. Wenguang W, Xuefeng W, Zhiping Z, Xiangsong W, Jianwei W, Songgang L, et al. Three-step method for lymphadenectomy in gastric cancer surgery: A single institution experience of 120 cases. J Am Coll Surg 2011; 212: 200-208.
2. Slattery ML, Sweeney C, Wolff R, Herrick J, Baumgartner K, Giuliano A, et al. Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res Treat 2007; 104: 197-209.
3. Belfiore A, Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011; 18: R125-R147.
4. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, et al. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet 2011; 20: 2263-2272.
5. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 2005; 307: 1976-1978.
6. Lin IH, Ho ML, Chen HY, Lee HS, Huang CC, Chu YH, et al. Smoking, green tea consumption, genetic polymorphisms in the insulin-like growth factors and lung cancer risk. PLoS One 2012; 7: e30951.
7. Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 2011; 58: 949-954.
8. Li ML, Zhang JC, Li SG, Wu WG, Rao LH, Dong P, et al. Characteristic gene expression profiles in the progression from normal gastric epithelial cells to moderate gastric epithelial dysplasia and to gastric cancer. Chin Med J 2012; 125: 1777-1783.
9. Li ML, Li SG, Wu WG, Rao LH, Zhang L, Ding QC, et al. Differential gene expression profiles of gastric cancer (in Chinese). Natl Med J China 2012; 92: 1249-1252.
10. McGrath M, Lee IM, Buring J, De Vivo I. Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol Oncol 2011; 120: 174-178.
11. Feik E, Baierl A, Hieger B, Fuhrlinger G, Pentz A, Stattner S, et al. Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 2010; 21: 91-97.
12. O'Dell SD, Miller GJ, Cooper JA, Hindmarsh PC, Pringle PJ, Ford H, et al. Apal polymorphism in insulin-like growth factor II (IGF2) gene and weight in middle-aged males. Int J Obes Relat Metab Disord 1997; 21: 822-825.
13. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocr Metab 2001; 86: 1274-1280.
14. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009; 30: 417-437.
15. Zou XN, Duan JJ, Huangfu XM, Chen WQ, Zhao P. Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China, 2004-2005 (in Chinese). Chin J Prev Med 2010; 44: 390-397.
16. Tan IB, Ng I, Tai WM, Tan P. Understanding the genetic basis of gastric cancer: recent advances. Expert Rev Gastroenterol Hepatol 2012; 6: 335-341.
17. Kudo T, Kane T, Fujinami H, Nishikawa J, Miyazaki T, Sugiyama T. Role of host genetic factors in gastric carcinogenesis. Nihon Rinsho 2009; 67: 2257-2262.
18. Tian F, Tang Z, Song G, Pan Y, He B, Bao Q, et al. Loss of imprinting of IGF2 correlates with hypomethylation of the H19 differentially methylated region in the tumor tissue of colorectal cancer patients. Mol Med Report 2012; 5: 1536-1540.
19. Dai X, Liu Z, Ren J, Wu G. Association between insulin-like growth factor binding protein-3 promoter polymorphism of-1590 C>A and lung cancer susceptibility in a Chinese Han population. Genet Test Mol Biomarkers 2011; 15: 301-306.
20. Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, et al. Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 2012; 23: 347-354.
21. Bosch-Barrera J, Hernandez A, Abella LE. Insulin and insulinlike growth factor pathway, a new targeted therapy in oncology. An Sist Sanit Navar 2009; 32: 413-421.
22. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, et al. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 2012; 36: 206-211.
23. Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, et al. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 2012; 131: E105-E113.
24. Riedl S, Kluge M, Schweitzer K, Waldhor T, Frisch H. Adaptation of ghrelin and the GH/IGF axis to high altitude. Eur J Endocrinol 2012; 166: 969-976.
25. Levine AJ, Ihenacho U, Lee W, Figueiredo JC, Vandenberg DJ, Edlund CK, et al. Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int J Colorectal Dis 2012; 27: 1587-1595.
26. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
27. Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, et al. Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet 2011; 20: 2263-2272.
28. Kim YJ, Yoon JH, Kim CY, Kim LH, Park BL, Shin HD, et al. IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. Biochem Biophys Res Commun 2006; 346: 38-44.
29. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006; 94: 299-307.